Despite the lack of a full direct experimental validation of CA20 as a surrogate of CA levels, our observations are very consistent with known CA’s features, namely CA20’s upregulation in cancer [7] and in basal-like breast tumours [26], and its association with the knock-down of centriole duplication factors, genomic instability [11], loss of p53 [6,7,35] and pRB [44], hypoxia [54,55] and worse patient’s prognosis [7]. This evidence concerns the gene TP53 and cancer.